Medical network on July 19 - recently, shandong food drug administration issued "about further promote transformation and upgrading of medicine circulation industry innovation and development of opinion (draft)", will promote the drug circulation enterprise merger and reorganization, explore new model drug circulation, etc.
The personage inside course of study is generally believed that this acquisition for large circulation drug firms in shandong market clearing the small business policy barriers. Previously, billions of drug circulation in the market of shandong province, about 620 points.
Sinopharm senior industry researcher dry RongFu to 21st century business herald reporters that the draft is in order to perform two votes, out of a batch of small and medium-sized enterprises, medicine circulation industry concentration will further improve in the future.
Association of Chinese pharmaceutical business supply chain branch secretary-general Zhu Jianyun pointed out that in addition to shandong, henan and other provinces have encouraged large circulation drug firms development policy, to allow open cities in the province branch, collective enterprises share the logistics distribution, developing warehouse business, etc. "But in the end choose distribution enterprises, the network and logistics service ability, two terminal channel capacity."
In the 21st century economic report reporter interview, head of the small and medium-sized pharmaceutical circulation enterprises, is currently transformation or waiting for the takeover. Multiple, head of the pharmaceutical production enterprise also to 21st century business herald reporters that due to the implementation of two votes, ended with some small and medium-sized wholesalers cooperation. "In the past we have to cooperate with some small and medium-sized wholesalers, because many of them are there is a close relationship with the hospital management of enterprises, in the middle to a vote, basic it is cooperation with large pharmaceutical circulation business now." A drug firms in shenzhen officials said.
Shandong billions of market change
Has caused quite a shock after draft issued: shandong pharmaceutical circulation billions of market will be stirred, characters, China resources, department of medicine, kyushu system is about to break into, shandong market or acquisitions.
Paper first pointed out, will promote the drug circulation enterprise merger restructuring, joint development, nurturing large-scale backbone enterprises, the modern medicine circulation that has been interpreted to mean, shandong pharmaceutical circulation market will face a merger and reorganization.
Paper also points out that supports medicine third-party logistics business and encourage drug-handling enterprise cross-regional distribution, explore new models of drug circulation which is for the large circulation enterprises in shandong market share clear policy barriers.
As mentioned, in the process of merger and acquisition of small and medium-sized medicine group, involving intercity relocation, enterprise restructuring, the storage and distribution facilities equipments is not lower than the original set up conditions; In the merger and reorganization, if the business address, quality management system unchanged, according to permit changes to deal with. To deal with variation of the pharmaceutical trade license may continue to operate, not out of business.
Shandong province is the largest pharmaceutical, released in June by the ministry of commerce the medicine circulation industry to run statistical analysis report, according to its sales number 7 in the country, a total of 2016 sales of 100.5 billion yuan, which ranked second in the national medical equipment sales.
Its group, medicine group and other national medicine circulation enterprises in shandong layout. In the shandong market share, however, the largest is the local enterprises in shandong Realcan Pharmaceutical Co., Ltd (hereinafter referred to as "red medicine"), the 2016 annual sales of 15.63 billion yuan, several other local medicine circulation enterprises in shandong also occupy a certain share, such as shandong shengshi conway Pharmaceutical Co., Ltd., shandong connor Pharmaceutical Co., Ltd., shandong xinhua Pharmaceutical trade Co., Ltd, the sales amount is 2.2 billion yuan respectively, 2016, 1.734 billion yuan, 1.388 billion yuan.
To draft, rui kang pharmaceutical related to 21st century business herald, head of the reporters, this will be good characters, medicine and other large enterprises, as well as good local leading enterprises such as medicine. "National medicine before with the acquisition of local enterprises entered shandong rui kang medicine is still in the leading advantage, shandong more than its market share."
Rui kang pharmaceutical is through mergers and acquisitions to grow continuously, and gradually by the regional leading enterprises to the enterprise development. Since 2015, rui kang medicine to speed up the quality of the acquisition of the circulation of medicines and chemical reagents, instruments, small and medium enterprises, more than 30 provinces in the country launched a takeover holding medical equipment company is given priority to, acquire pharmaceutical trading company is complementary, fujian association of foreign languages and expansion.
Branch secretary general of the association of Chinese pharmaceutical business supply chain Zhu Jianyun to 21st century business herald reporters that encourage merger and acquisition of policy guidance, medicine circulation enterprises in shandong province concentration will increase further, many small and medium enterprises will face by merger or transformation of the situation, characters, China resources, the prescription, kyushu or will occupy the market share of small and medium-sized enterprises.
Other analysts believe that the small and medium-sized pharmaceutical circulation enterprises, or become a few big circulation channel distribution of giant enterprises, or takes specialization differentiation course, such as focus on the field of a disease or a segment of the market. "This 620 pharmaceutical wholesale enterprises most will disappear, or be mergers and acquisitions, or failure."
"Big small" is inevitable
For the above comment draft is not a case of shandong province, June 26, in henan province food drug administration issued a similar to encourage large circulation enterprises merger policy. In dry RongFu point of view, it represents the future trend, a large number of small and medium-sized pharmaceutical circulation enterprises or closure or be acquired.
Provincial policy from this year on February 9, issued by the general office of the state council concerning the further reform and improve the use policy for producing and distributing medicines of several opinions (13), it points out that to promote drug cross-regional, cross ownership merger and reorganization of enterprises and nurturing large-scale modern medicine circulation backbone enterprises, encourage small and medium-sized pharmaceutical circulation enterprises specialized operation, push some companies to channel distribution model transformation.
Ministry of commerce of medicine circulation industry in 2016, according to the annual report by the end of November 2016, the national total of pharmaceutical wholesale enterprises 12975, advocate business wu income before 100 market share of 70.9%, among them, the characters and the CRC, prescription, kyushu through four national leading enterprise main business income accounted for 37.4%, rose 0.5% from a year; 15 regional leading enterprise main business income accounted for 18.4%, rose 1.1% from a year.
Such as improve the circulation market concentration, will inevitably bring about a standardize tide, to eliminate irregularities. Previously, the CFDA safety supervision department Mr Li has pointed out, exit 1 m 1.3 wholesale enterprises in China, the remaining 3000 May be the ideal situation.
More than with the 21st century economic report of the small and medium-sized enterprises of reporter says, transformation or quit. A small pharmaceutical wholesale enterprises in yunnan province, said an official with multiple large pharmaceutical circulation business negotiation, choose a highest price, exit the pharmaceutical industry; Fujian, head of a small pharmaceutical wholesale enterprises complain that policy is unfair, helplessly transition now, but still no clear direction.
According to the 21st century economic report reporter understanding, many small and medium-sized pharmaceutical wholesale enterprises in Shanghai policy advice, different occasions, such as business conferences have expressed concerns survival. Shanghai pharmaceutical wholesale enterprises have 126 or so, medicine, the control has the absolute share advantages.
In Zhu Jianyun point of view, "bloody" situation is possible, but occur in small and medium-sized pharmaceutical circulation enterprises, large enterprises is to grab market share. "National medicine and so on four big national circulation enterprises has a national network of synergy, but in different areas may advantage than the local leading enterprises, such as local enterprises in chongqing chongqing pharmaceutical occupy most of the share, is the yunnan province of yunnan province pharmaceutical occupy the main market share, hunan, hubei, henan, its subsidiary is a local leading enterprises."
Shenzhen before what is more, so the reform of drug purchase in qualified pharmaceutical distribution enterprises designated by the medicine network, the exclusive bidding way to break the drug circulation pattern of interests, cause distribution enterprises, production enterprises and the public hospital many strong rebound, the last is the national development and reform commission as a monopoly.
Two votes 630 deadline
Dry RongFu reporter analysis into the 21st century economy, the paper is in order to better perform two votes, out of a batch of small and medium-sized enterprises, medicine circulation industry concentration will further improve in the future.
On July 13, such as health development planning commission of guangdong province officially released about asking for the public medical institutions and drug trade in guangdong province "two votes" implementation plan (implementation) "(draft), points out that distribution of traded varieties designated production enterprise shall cover the entire province all medical institutions participating in the drug trade, and in accordance with" interim measures for the pharmaceutical trade related medical institutions in guangdong province ", and cannot reach the province covering general small and medium-sized enterprises.
A don't want to be named the personage inside course of study to the 21st century economic report reporter pointed out that the large pharmaceutical circulation enterprises in compliance, resources, distributors have advantages in many aspects, but still there are many small and medium-sized wholesalers, because they have some "special" channel advantages, such as, good relationship with local hospital only from it into the hospital, and it is of two votes to regulate the behavior of these irregularities ticket.
Multiple, head of the pharmaceutical enterprise also to 21st century business herald reporters, because the two votes, ended with some small and medium-sized wholesalers cooperation. "In the past we have to cooperate with some small and medium-sized wholesalers, because many of them are there is a close relationship with the hospital management of enterprises, in the middle to a vote, basic it is cooperation with large pharmaceutical circulation business now." A drug firms in shenzhen, said an official with the now reduces unnecessary ticket.
Medicine development strategy, a researcher at MouQiong thinks, two votes policy with clear background and policy objectives, namely improve regulation integrated pharmaceutical circulation order, so can't be two votes viewed separately, but with the camp to increase, commercial bribery, gold three period, and so on regulatory move together.
From now, in the second half will be a crucial period for two votes to the ground. According to state no. 13 (17), and 2017 national health reform key tasks schedule requirements, is reform pilot province of two votes on June 30 deadline for papers, 11 health of the provinces, in addition to the ningxia almost all solution before the deadline.
"But every province in policy making, more or less will be inclined to provincial enterprises." The personage inside course of study points out above.
Such as zhejiang and determination in the production of enterprises in the two votes for draft, points out that on the pharmaceutical production enterprise or trade and integration of group enterprises set up wholly owned or holding companies (only 1 national commercial companies) in the sales of the enterprise (group) pharmaceutical group company, circulation in the sales of a wholly-owned subsidiary (holding) production of drugs can be regarded as production enterprise.
MouQiong analysis, zhejiang several big commercial leading almost all have their own pharmaceutical industry, the regulation is for integration of industrial and commercial enterprises in the province was the key to the production and circulation one vote, on the one hand, to promote industrial and commercial enterprise concentration, on the other hand, the policy is also spare no effort to encourage the province development of pharmaceutical industry. |
